Search results
Results from the WOW.Com Content Network
Blinatumomab linking a T cell to a malignant B cell. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor.
Blinatumomab: Treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in people aged one month of age and older [2] Budesonide: For twelve weeks of treatment in people aged eleven years of age and older with eosinophilic esophagitis [2]
1977 – US FDA approves tamoxifen for metastatic breast cancer only, not widely popular as chemotherapy remains first line of treatment [27] [28] 1981 – American Dr. Bernard Fisher proves lumpectomy is as effective as mastectomy for breast cancer [4] 1989 – US FDA approves Carboplatin, a derivative of cisplatin, for chemotherapy [10]
Time line for cancer chemotherapy A time line of milestones in cancer chemotherapy from the National Cancer Institute that includes recollections of people involved with the NCI effort. This was put together on the occasion of the 50th anniversary of the Cancer Chemotherapy National Service Center (CCNSC).
Neoadjuvant chemotherapy is given before surgery to slow the growth of a fast-growing cancer or to shrink the size of a larger breast cancer. [ 1 ] It is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too large to be removed by surgery, which can then be removed with less extensive surgery.
Blue Cross Blue Shield payments to about 6 million people are set to go out more than two years after the health insurer reached a $2.67 billion settlement with subscribers.
Brentuximab vedotin [6] consists of the chimeric monoclonal antibody brentuximab (cAC10, which targets the cell-membrane protein CD30) linked with maleimide attachment groups, cathepsin-cleavable linkers (valine-citrulline), and para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). [7]
Efficacy was evaluated in a multicenter, single-arm, open-label study in 53 pediatric participants aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. [8] Two dose levels were evaluated--an initial dose of 1.4 mg/m2/cycle in 12 participants and 1.8 mg/m2/cycle in 41 participants. [8]